Your session is about to expire
← Back to Search
Chemotherapy
Amifostine + Chemotherapy for Advanced Cancer
Phase 1
Waitlist Available
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Performance status: ECOG 0-2 SWOG 0-2
Hepatic: Bilirubin no greater than 1.5 mg/dL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying amifostine to see how well it works in combination with chemotherapy in treating patients with advanced cancer.
Who is the study for?
This trial is for adults with advanced cancers like leukemia, lymphoma, and solid tumors that respond to cyclophosphamide/carboplatin or are refractory to standard treatments. Participants must have certain blood cell counts, not be pregnant or nursing, use contraception if fertile, have no severe heart disease or psychosis, and a life expectancy of at least 3 months.Check my eligibility
What is being tested?
The study is testing the effectiveness of amifostine combined with chemotherapy in patients with advanced cancer. Amifostine is intended to protect healthy cells from the harmful side effects of chemotherapy drugs.See study design
What are the potential side effects?
Potential side effects may include nausea, vomiting, low blood pressure (especially following injection), dizziness upon standing up due to lowered blood pressure, and allergic reactions. Chemotherapy can also cause fatigue, hair loss, mouth sores and increased risk of infections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can take care of myself and perform daily activities.
Select...
My bilirubin level is 1.5 mg/dL or lower.
Select...
I am 18 years old or older.
Select...
I do not have severe heart disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
The Cleveland ClinicLead Sponsor
1,019 Previous Clinical Trials
1,365,045 Total Patients Enrolled
9 Trials studying Multiple Myeloma
175 Patients Enrolled for Multiple Myeloma
George Thomas Budd, MDStudy ChairThe Cleveland Clinic
3 Previous Clinical Trials
4,794 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer responds to or is resistant to standard treatments.I can take care of myself and perform daily activities.My bilirubin level is 1.5 mg/dL or lower.I am not currently on any immunotherapy treatments.I stopped hormone therapy at least a week ago and feel recovered. I may be on steroids.I am 18 years old or older.I've had only one chemotherapy for advanced cancer, it's been 3 weeks since, and I've recovered.I had radiotherapy 3 weeks ago or longer and have recovered.It's been over 3 weeks since my last surgery and I've recovered.My kidney function is normal, based on creatinine levels or clearance tests.I do not have severe heart disease.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there available slots for participants in this research endeavor?
"According to the clinicaltrials.gov database, this experiment is no longer accepting enrollees. It was initiated on November 1st 1997 and last updated 18th December 2013. Alternatively, there are 4,910 other trials that remain open for new participants at present."
Answered by AI
Has this remedy obtained authorization from the Food and Drug Administration?
"Based on the limited data collected, Power's assessment is that this treatment holds a low level of safety, evidenced by its Phase 1 status."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger